About 1 100 reports

pathology.

  • Pathology
  • Therapy
  • World
  • Supply
  • Medestea

## (Cyclooxygenase-## or COX-## or Prostaglandin- Endoperoxide Synthase ## or EC ##. ##. ##. ##) Prostaglandin G/ H Synthase ## (Cyclooxygenase-## or COX-## or Prostaglandin- Endoperoxide Synthase ## or EC ##. ##. ##. ##) ## ## ## ## ## ## ## ## ## ALK Tyrosine Kinase

  • Pathology
  • United States
  • Auspex Pharmaceuticals, Inc.
  • Cephalon, Inc.
  • ChemGenex Pharmaceuticals Limited

Lung damage pathology is caused by both influenza virus infection and expansion, and the body' s immune response to fight the infection.

  • Influenza
  • Pathology
  • Vaccine
  • United States
  • Product Initiative

Additionally, two patients underwent surgery following aldoxorubicin treatment, and the pathology analysis of the removed tissue showed no viable tumor.

  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Kadmon Corporation, LLC

It develops therapeutics for nervous system pathologies involving human endogenous retroviruses.

  • Neurological Disorder
  • Pathology
  • United States
  • World
  • Product Initiative

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Kadmon Corporation, LLC

The molecules developed by Companies in Phase I, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Neurological Disorder
  • Pathology
  • United States
  • World
  • AndroScience Corporation, Inc

This vector was confirmed to provide GAA expression and activity in target tissues, improved muscle pathology and a favorable immunogenicity profile.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Amicus Therapeutics

The molecules developed by companies in Phase II, Phase ##, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Virobay Inc.

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Neurology
  • Pathology
  • Therapy
  • Type 2 Diabetes
  • Regeneron Pharmaceuticals, Inc.

The drug candidate acts by dual mechanism, it targets heparanase enzyme, VEGF, FGF-##, FGF-##.

  • Cancer
  • Oncology
  • Pathology
  • Pharmaceutical
  • Therapy

The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Neurological Disorder
  • Pathology
  • United States
  • World
  • AndroScience Corporation, Inc

In part ##, patients will be randomized on a ##:##:## basis to receive one of two active doses (## mg or ## mg) of PRX##/ RG## or placebo via intravenous infusion once every ## weeks.

  • Pathology
  • United States
  • World
  • Company
  • Product Initiative

The molecules developed by Companies in Phase II and Preclinical stages are ## and ## respectively.

  • Pathology
  • United States
  • World
  • Product Initiative
  • AbbVie Inc.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Genetic Engineering
  • Pathology
  • United States
  • World
  • Product Initiative

Down Syndrome - Overview Down Syndrome - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR DOWN SYNDROME, H## 2018 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR DOWN SYNDROME, H## 2018 Phase I ## ## Preclinical ## ## Discovery ## ## Unknown ## ## Total ## ## NUMBER OF PROD

  • Dementia
  • Pathology
  • United States
  • World
  • Product Initiative

The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical and Discovery stages are ##, ##, ##, ##, ## and ## respectively.

  • Pathology
  • Vaccine
  • United States
  • World
  • Product Initiative

The molecules developed by Companies in Phase III, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Cardiovascular Disease
  • Pathology
  • World
  • Product Initiative
  • Evotec AG

Patients were randomized to one of five treatment groups in a ##:##:##:##:## fashion: fasinumab ##mg, ##mg, ##mg, ##mg, or placebo, all delivered subcutaneously every ## weeks through week ##, with the primary efficacy measured at week ##.

  • Chronic Pain
  • Pathology
  • World
  • Product Initiative
  • Pfizer Inc.

ACE-## is currently being evaluated in two Phase ## trials: one in FSHD and one in Charcot-Marie-Tooth (CMT) disease.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Acceleron Pharma, Inc.

The molecules developed by Companies in Phase II and Preclinical stages are ## and ## respectively.

  • Neurological Disorder
  • Pathology
  • World
  • Product Initiative
  • Pfizer Inc.

The molecules developed by companies in Phase II, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Clinical Trial
  • Pathology
  • Therapy
  • World
  • Product Initiative

Sanyal, MD, lead study author and Professor of Medicine, Physiology and Molecular Pathology, School of Medicine at Virginia Commonwealth University.

  • Pathology
  • Therapy
  • World
  • Product Initiative
  • Gilead Sciences, Inc.

At the end of the experimental period (## days) mice were imaged using T##-weighted MRI for brainstem pathology; brain and spinal cord tissue were then collected for histological analysis.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Biogen Idec Inc.

The molecules developed by Companies in Phase II and Preclinical stages are ## and ## respectively.

  • Pathology
  • United States
  • World
  • Product Initiative
  • AbbVie Inc.

The alpha-synuclein mouse model progressively develops pathology which leads to functional impairment and is useful to identify potential diseasemodifying therapeutics.

  • Pathology
  • Psychotic Disorder
  • United States
  • World
  • Product Initiative

Anakinra blocks the biologic activity of interleukin-## by competitively inhibiting interleukin-## binding to the interleukin-## type I receptor (IL ##RI), which is expressed in a wide variety of tissues and organs.

  • Cardiovascular Disease
  • Pathology
  • World
  • Product Initiative
  • Evotec AG

The FDA also provisionally indicated that existing toxicology and pathology studies can support clinical development with AEVI-##.

  • Pathology
  • Therapy
  • United States
  • World
  • Product Initiative

It offers preventative treatment on the diagnosis of amyloid plaque pathology before dementia.

  • Pathology
  • United States
  • World
  • Product Initiative
  • NeuroGenetic Pharmaceuticals, Inc.